Newsfeeds - Spark Newswire

1 minute read

Piper Sandler Initiates Coverage On Cue Biopharma with Overweight Rating, Announces Price Target of $7

Today, 10:07 AM

Piper Sandler analyst Edward Tenthoff initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Overweight rating and announces Price Target of $7.

CUE

3 minute read

Why Soluna Holdings Shares Are Trading Sharply Lower; Here Are 38 Stocks Moving Premarket

By Lisa Levin

Today, 10:07 AM

Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) rose 70.8% to $0.41 in pre-market trading. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation.

AGTC

25 minute read

Options

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 10:07 AM

During Monday's session, 402 companies made new 52-week lows.

AAL

1 minute read

Oppenheimer Maintains Outperform on Cue Biopharma, Lowers Price Target to $10

By Benzinga Newsdesk

Today, 10:07 AM

Oppenheimer analyst Mark Breidenbach maintains Cue Biopharma (NASDAQ:CUE) with a Outperform and lowers the price target from $26 to $10.

CUE

3 minute read

Recap Of Monday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

Today, 10:07 AM

The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery…

BLTE

1 minute read

Cue Biopharma Shares Decline Following Initial-Stage Metastatic Cancer Study Kicks-off

By Ragothaman Srinivasan

Today, 10:07 AM

Cue Biopharma (NASDAQ: CUE) has dosed the first patient in a Phase 1 dose escalation study evaluating CUE-102 for the treatment of patients with Wilms' Tumor 1 (WT1)-positive recurrent/metastatic cancers.

CUE

12 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 10:07 AM

On Friday, 319 stocks hit new 52-week lows.

ADI

6 minute read

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 10:07 AM

On Tuesday, 87 companies hit new 52-week lows.

ACVA

44 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 10:07 AM

On Wednesday, 807 companies reached new 52-week lows.

AADI

1 minute read

FDA Accepts IND for Cue Biopharma’s CUE-102 in the treatment of Wilms’ Tumor 1 (WT1)

By Ragothaman Srinivasan

Today, 10:07 AM

Cue Biopharma, Inc. (NASDAQ: CUE) received the U.S. Food and Drug Administration (FDA) acceptance of the Investigational New Drug (IND) application for the evaluation of CUE-102 in the treatment of Wilms' Tumor 1 (WT1)-positive recurrent/metastatic cancers.

CUE